肌层浸润性膀胱癌新辅助剂量密集MVAC与吉西他滨联合顺铂的病理反应和生存比较
该回顾性多中心研究纳入2000至2015年20家机构中接受新辅助化疗后行根治性膀胱切除术的cT3-4aN0M0膀胱尿路上皮癌患者319例,比较剂量密集MVAC与吉西他滨联合顺铂的病理反应和生存。结果显示剂量密集MVAC组ypT0N0率更高(28.0% vs 14.6%,p=0.005),总生存更优(平均7.0年 vs 4.2年,p=0.001),术前数据多因素分析中吉西他滨联合顺铂组死亡风险更高(HR 2.07,95%CI 1.25-3.42,p=0.003)。
要点
- 剂量密集MVAC组ypT0N0率显著高于吉西他滨联合顺铂组(28.0% vs 14.6%,p=0.005)。
- 剂量密集MVAC组平均总生存7.0年,吉西他滨联合顺铂组4.2年(p=0.001)。
- 术前数据多因素分析显示吉西他滨联合顺铂组死亡风险更高(HR 2.07,95%CI 1.25-3.42,p=0.003)。
核心结论
- 在局部晚期膀胱癌回顾性队列中,剂量密集MVAC与新辅助吉西他滨联合顺铂相比,与更高的病理完全缓解率和更优的生存率相关。
- 作者认为需要临床试验验证这些假设生成性结果,以检验剂量密集MVAC在局部晚期膀胱癌患者中的优越性。
研究设计与样本
- 回顾性多中心队列研究,纳入2000至2015年20家机构中接受新辅助化疗后行根治性膀胱切除术的尿路上皮癌患者。
- 分析对象为cT3-4aN0M0疾病患者,共319例符合纳入标准。
- 比较吉西他滨联合顺铂与剂量密集MVAC方案的ypT0N0率和ypT1N0或更低率。
- 使用术前和术后数据分别建立两个多因素Cox比例风险回归模型分析总死亡。
主要发现
- 吉西他滨联合顺铂组ypT0N0率显著低于剂量密集MVAC组(14.6% vs 28.0%,p=0.005)。
- 吉西他滨联合顺铂组ypT1N0或更低率为30.1%,剂量密集MVAC组为41.0%(p=0.07)。
- 吉西他滨联合顺铂组和剂量密集MVAC组的平均Kaplan-Meier总生存估计分别为4.2年和7.0年(p=0.001)。
- 基于术前数据的多因素Cox回归分析中,吉西他滨联合顺铂组死亡风险高于剂量密集MVAC组(HR 2.07,95%CI 1.25-3.42,p=0.003)。
- 淋巴结侵犯(HR 1.97,95%CI 1.15-3.36,p=0.01)和肾积水(HR 2.18,95%CI 1.43-3.30,p<0.001)也与更高死亡风险相关。
关键数值与推荐
- ypT0N0率:吉西他滨联合顺铂组14.6%,剂量密集MVAC组28.0%(p=0.005)。
- ypT1N0或更低率:吉西他滨联合顺铂组30.1%,剂量密集MVAC组41.0%(p=0.07)。
- 平均总生存:吉西他滨联合顺铂组4.2年,剂量密集MVAC组7.0年(p=0.001)。
- 术前数据多因素分析死亡风险:吉西他滨联合顺铂组相对剂量密集MVAC组HR 2.07(95%CI 1.25-3.42,p=0.003)。
- 死亡风险因素:淋巴结侵犯HR 1.97(95%CI 1.15-3.36,p=0.01),肾积水HR 2.18(95%CI 1.43-3.30,p<0.001)。
临床怎么用
- 对于cT3-4aN0M0局部晚期膀胱癌患者,剂量密集MVAC新辅助化疗可能与更高的病理完全缓解率和更优生存相关。
- 吉西他滨联合顺铂组死亡风险较高,临床决策时可结合患者耐受性和预后因素个体化选择新辅助方案。
- 淋巴结侵犯和肾积水与更高死亡风险相关,可作为预后评估的参考因素。
局限性
- 本研究为回顾性队列研究,存在选择偏倚等固有局限。
- 结果属于假设生成性,需前瞻性临床试验验证剂量密集MVAC的优越性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Level I evidence supports the usefulness of neoadjuvant cisplatin based chemotherapy for muscle invasive bladder cancer. Since dose dense MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) has mostly replaced traditional MVAC, we compared pathological response and survival rates in patients with locally advanced bladder cancer who received neoadjuvant chemotherapy with dose dense MVAC vs gemcitabine and cisplatin. MATERIALS AND METHODS: We retrospectively reviewed the records of patients with urothelial cancer who received neoadjuvant chemotherapy and underwent cystectomy at a total of 20 contributing institutions from 2000 to 2015. Patients with cT3-4aN0M0 disease were selected for this analysis. The rates of ypT0N0 and ypT1N0 or less were compared between the gemcitabine and cisplatin, and dose dense MVAC regimens. Two multivariable Cox proportional hazards regression models of overall mortality were generated using preoperative and postoperative data. RESULTS: Of the patients who underwent neoadjuvant chemotherapy and radical cystectomy during the study period 319 met our inclusion criteria. A significantly lower rate of ypT0N0 was observed in the gemcitabine and cisplatin arm than in the dose dense MVAC arm (14.6% vs 28.0%, p = 0.005). The rate of ypT1N0 or less was 30.1% for gemcitabine and cisplatin compared to 41.0% for dose dense MVAC (p = 0.07). The mean Kaplan-Meier estimates of overall survival in the gemcitabine and cisplatin, and dose dense MVAC groups were 4.2 and 7.0 years, respectively (p = 0.001). On multivariable cox regression analysis based on preoperative data patients who received gemcitabine and cisplatin were at higher risk for death than patients who received dose dense MVAC (HR 2.07, 95% CI 1.25-3.42, p = 0.003). Lymph node invasion (HR 1.97, 95% CI 1.15-3.36, p = 0.01) and hydronephrosis (HR 2.18, 95% CI 1.43-3.30, p <0.001) were also associated with higher risk of death. CONCLUSIONS: In our retrospective cohort of patients with locally advanced bladder cancer dose dense MVAC was associated with higher complete pathological response and improved survival rates compared to gemcitabine and cisplatin. A clinical trial is warranted to validate these hypothesis generating results to test the superiority of neoadjuvant dose dense MVAC in patients with locally advanced bladder cancer.
引用
- Zargar H, Shah JB, van Rhijn BW, et al. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy. J Urol. 2018. PMID: 29329894. doi:10.1016/j.juro.2017.12.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。